Faculty

Saar I Gill, MD, PhD

faculty photo
Assistant Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine
Graduate Group Affiliations

Contact information
Room 8-101
Smilow Translational Research Center
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: (215) 573-4015
Lab: (215) 573-4015
Education:
MBBS (medicine)
University of Melbourne, 1999.
PhD (immunology)
University of Melbourne, 2011.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

Blood and Marrow Transplantation
Leukemia
Myelodysplastic Syndromes
Myeloproliferative Neoplasms
Lymphoproliferative Neoplasms
Bone Marrow Failure

Description of Research Expertise

Tumor Immunology
Chimeric Antigen Receptor T cells
Mouse Models of Human Leukemia
Murine Xenografts
Adoptive Cellular Therapy
Genetic Engineering of T cells
Flow Cytometry

Selected Publications

Kim GYG, Burns J, Freyer CW, Hamilton KW, Frey NV, Gill SI, Hexner EO, Luger SM, Mangan JK, Martin ME, McCurdy SR, Perl AE, Porter DL, Schuster MG, Stadtmauer EA, Loren AW: Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents. Am J Hematol 95(7): 792-798, Jul 2020

Frey NV, Gill S, Hexner EO, Schuster S, Nasta S, Loren A, Svoboda J, Stadtmauer E, Landsburg DJ, Mato A, Levine BL, Lacey SF, Melenhorst JJ, Veloso E, Gaymon A, Pequignot E, Shan X, Hwang WT, June CH, Porter DL: Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol Page: JCO1903237, Apr 16 2020 Notes: doi: 10.1200/JCO.19.03237.

Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, Schmierer M, Gabrusiewicz K, Anderson NR, Petty NE, Cummins KD, Shen F, Shan X, Veliz K, Blouch K, Yashiro-Ohtani Y, Kenderian SS, Kim MY, O'Connor RS, Wallace SR, Kozlowski MS, Marchione DM, Shestov M, Garcia BA, June CH, Gill S. : Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol 38(8): 947-953, Aug 2020.

Brian J Ball, Christopher A Famulare, Eytan M Stein, Martin S Tallman, Andriy Derkach, Mikhail Roshal, Saar I Gill, Benjamin M Manning, Jamie Koprivnikar, James McCloskey, Rebecca Testi, Thomas Prebet, Najla H Al Ali, Eric Padron, David A Sallman, Rami S Komrokji, Aaron D Goldberg : Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Adv 4(13): 2866-2870, Jul 14 2020.

Freyer CW, Carulli A, Ganetsky A, Hughes ME, Krause TM, Timlin C, Frey NV, Gill SI, Hexner EO, Loren AW, Mangan JK, Martin ME, McCurdy SR, Perl AE, Pratz K, Porter DL, Luger SM.: Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementation. Leuk Lymphoma Page: 1-8, Jun 1 2020 Notes: doi: 10.1080/10428194.2020.1765239.

Mardiana S, Gill S.: CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions. Front Oncol 10: 697, May 6 2020 Notes: doi: 10.3389/fonc.2020.00697.

Singh N, Lee YG, Shestova O, Ravikumar P, Hayer KE, Hong SJ, Lu XM, Pajarillo R, Agarwal S, Kuramitsu S, Orlando EJ, Mueller KT, Good CR, Berger SL, Shalem O, Weitzman MD, Frey NV, Maude SL, Grupp SA, June CH, Gill S, Ruella M.: Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction. Cancer Discov 10(4): 552-567, Apr 2020.

Nobles CL, Sherrill-Mix S, Everett JK, Reddy S, Fraietta JA, Porter DL, Frey N, Gill SI, Grupp SA, Maude SL, Siegel DL, Levine BL, June CH, Lacey SF, Melenhorst JJ, Bushman FD.: CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. J Clin Invest 130(2): 673-685, Feb 3 2020.

Finck A, Gill SI, June CH.: Cancer immunotherapy comes of age and looks for maturity. Nature Communications 11(1): 3325, 2020.

Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, Mangan JK, Loren AW, Perl AE, Maude SL, Grupp SA, Shah NN, Gilmore J, Lacey SF, Melenhorst JJ, Levine BL, June CH, Porter DL.: Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. J Clin Oncol. Page: JCO1901892, Dec 9 2019 Notes: DOI: 10.1200/JCO.19.01892.

back to top
Last updated: 08/25/2020
The Trustees of the University of Pennsylvania